scholarly journals Evaluation of an Early Regression Index (ERITCP) as Predictor of Pathological Complete Response in Cervical Cancer: A Pilot-Study

2020 ◽  
Vol 10 (22) ◽  
pp. 8001
Author(s):  
Davide Cusumano ◽  
Francesco Catucci ◽  
Angela Romano ◽  
Luca Boldrini ◽  
Antonio Piras ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Pathological Complete Response ◽  
Predictive Performance ◽  
Response Prediction ◽  
Complete Response ◽  
Mr Images ◽  
Low Field ◽  
Response Biomarker ◽  
Regression Index ◽  
Treatment Response Prediction

Background: Recent studies have highlighted the potentialities of a radiobiological parameter, the early regression index (ERITCP), in the treatment response prediction for rectal cancer patients treated with chemoradiotherapy followed by surgery. The aim of this study is to evaluate the performance of this parameter in predicting pathological complete response (pCR) in the context of low field MR guided radiotherapy (MRgRT) for cervical cancer (CC). Methods: A total of 16 patients affected by CC were enrolled. All patients underwent a MRgRT treatment, with prescription of 50.6 Gy in 22 fractions. A daily MR acquisition was performed at simulation and on each treatment fraction. Gross tumor volume (GTV) was delineated on the MR images acquired at the following biological effective dose (BED) levels: 14, 28, 42, 54 and 62 Gy. The ERITCP was calculated at the different BED levels and its predictive performance was quantified in terms of receiver operating characteristic (ROC) curve. Results: pCR was observed in 11/16 cases. The highest discriminative power of ERITCP was reported when a BED value of 28 Gy is reached, obtaining an area under curve (AUC) of 0.84. Conclusion: This study confirmed ERITCP as a promising response biomarker also for CC, although further studies with larger cohort of patients are recommended.

scholarly journals Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Fengling Li ◽  
Yongquan Yang ◽  
Yani Wei ◽  
Ping He ◽  
Jie Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Deep Learning ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pathological Complete Response ◽  
Predictive Biomarkers ◽  
Predictive Performance ◽  
Complete Response ◽  
Breast Cancer Patients ◽  
Histological Images

Abstract Background Pathological complete response (pCR) is considered a surrogate endpoint for favorable survival in breast cancer patients treated with neoadjuvant chemotherapy (NAC). Predictive biomarkers of treatment response are crucial for guiding treatment decisions. With the hypothesis that histological information on tumor biopsy images could predict NAC response in breast cancer, we proposed a novel deep learning (DL)-based biomarker that predicts pCR from images of hematoxylin and eosin (H&E)-stained tissue and evaluated its predictive performance. Methods In total, 540 breast cancer patients receiving standard NAC were enrolled. Based on H&E-stained images, DL methods were employed to automatically identify tumor epithelium and predict pCR by scoring the identified tumor epithelium to produce a histopathological biomarker, the pCR-score. The predictive performance of the pCR-score was assessed and compared with that of conventional biomarkers including stromal tumor-infiltrating lymphocytes (sTILs) and subtype. Results The pCR-score derived from H&E staining achieved an area under the curve (AUC) of 0.847 in predicting pCR directly, and achieved accuracy, F1 score, and AUC of 0.853, 0.503, and 0.822 processed by the logistic regression method, respectively, higher than either sTILs or subtype; a prediction model of pCR constructed by integrating sTILs, subtype and pCR-score yielded a mean AUC of 0.890, outperforming the baseline sTIL-subtype model by 0.051 (0.839, P  =  0.001). Conclusion The DL-based pCR-score from histological images is predictive of pCR better than sTILs and subtype, and holds the great potentials for a more accurate stratification of patients for NAC.

scholarly journals Efficacy of dose-intensive platinum-containing neoadjuvant chemotherapy in the combination treatment for locally advanced cervical cancer

2019 ◽  
Vol 14 (4) ◽  
pp. 56-64
Author(s):  
O. A. Smirnova ◽  
N. E. Bondarev ◽  
E. A. Ulrikh ◽  
N. A. Mikaya ◽  
A. S. Petrova ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Pathological Complete Response ◽  
Objective Response ◽  
Locally Advanced ◽  
Complete Response ◽  
Small Sample ◽  
Pathological Response ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer

Objective:to assess the efficacy of dose-intensive platinum-containing neoadjuvant chemotherapy in patients with FIGO stage IB2–IIB locally advanced cervical cancer.Materials and methods.We evaluated the efficacy and toxicity of 3 cycles of intravenous dose-intensive neoadjuvant chemotherapy with either AP regimen (cisplatin 75 mg/m2 and doxorubicin 35 mg/m2) or TP regimen (cisplatin 60 mg/m2 and paclitaxel 60 mg/m2).Results.The study included 105 patients (75 in the AP group and 30 in the TP group) aged between 27 and 63 years (mean age 44 years) with primary verified cervical cancer (T1–2B0–2Nx–0M0). Surgery was performed in 66 patients (88 %) from the AP group and 24 patients (80 %) from the TP group. Six patients (8 %) receiving AP regimen and 1 patient (3.3 %) receiving TP regimen developed disease progression. Four women (2.8 %) from the AP group developed relapses, whereas none of the patients from the TP group had relapses. Dose-intensive chemotherapy did not cause any significant complications at both chemotherapeutic and surgical stages. Our findings suggest that dose-intensive neoadjuvant chemotherapy is an effective method with an objective response rate of 84 % (63 cases) and 56.7 % (17 cases) in groups AP and TP respectively. Fifty-nine patients (78.7 %) receiving AP regimen had pathological response; of them, 7 participants (9.4 %) demonstrated pathological complete response (ypCR). In the TP group, 19 patients (63.3 %) had pathological response and 4 patients (13.4 %) had pathological complete response. Median follow-up time was 16.7 months (range: 3–29 months) in the AP group and 9.1 months (range: 2.8–12.7 months) in the TP group.Conclusion.Dose-intensive neoadjuvant chemotherapy can be considered as an alternative to standard treatment of locally advanced cervical cancer; however, further studies are needed due to the small sample size in this study.

scholarly journals A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database

2020 ◽  
Vol 73 ◽  
pp. 148-151
Author(s):  
Michael Z. Liu ◽  
Simukayi Mutasa ◽  
Peter Chang ◽  
Maham Siddique ◽  
Sachin Jambawalikar ◽  
...  
Keyword(s):  
Pathological Complete Response ◽  
Breast Mri ◽  
Response Prediction ◽  
Complete Response

scholarly journals OC-0317: MR radiomics and fractal dimension in cervical cancer predicting pathological complete response

2017 ◽  
Vol 123 ◽  
pp. S164-S165
Author(s):  
N. Dinapoli ◽  
A.L. Valentini ◽  
A. Pesce ◽  
R . Gatta ◽  
C. Masciocchi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Fractal Dimension ◽  
Pathological Complete Response ◽  
Complete Response

Fertility-Sparing Management for Bulky Cervical Cancer Using Neoadjuvant Transuterine Arterial Chemotherapy Followed by Vaginal Trachelectomy

2012 ◽  
Vol 22 (6) ◽  
pp. 1057-1062 ◽  
Author(s):  
Hiroshi Tsubamoto ◽  
Riichiro Kanazawa ◽  
Kayo Inoue ◽  
Yoshihiro Ito ◽  
Shinji Komori ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Medical Records ◽  
Pathological Complete Response ◽  
Complete Response ◽  
International Federation ◽  
Maximum Diameter ◽  
Gynecology And Obstetrics ◽  
Fertility Sparing ◽  
Disease Free

BackgroundFertility-sparing management for bulky cervical cancer remains under investigation. We investigated the safety of neoadjuvant transuterine arterial chemotherapy (TUAC) followed by a simple vaginal trachelectomy for patients with tumors larger than 3 cm in diameter who desired uterine preservation.MethodsFirst, to assess the safety and efficacy of TUAC, survival and pathological complete response data from 39 patients with a diagnosis of stage IB2 to stage IIB cervical cancer who participated in 2 consecutive trials during 1997–2006 were analyzed. The neoadjuvant chemotherapy regimens were a combination of TUAC using cisplatin with intravenous nedaplatin or irinotecan. Second, to assess the safety of fertility-sparing management with TUAC, medical records of patients matching the following criteria were reviewed during the same period: (1) International Federation of Gynecology and Obstetrics stages IB1 to IIA; (2) maximum diameter of tumor, 3 cm or more; (3) squamous cell carcinoma; (4) no radiological findings of lymph node metastasis; and (5) patient’s strong desire for preservation of the uterus and to undergo TUAC.ResultsThe overall 5-year survival rate of the 39 enrolled patients was 81.0% (95% confidence interval, 64.8%–93.7%). No malignant cells were found in pathologically examined surgical specimens from 14 patients (35.9%), all of whom were alive without recurrence for more than 7 years after treatment. Based on medical records, 7 patients were eligible according to the fertility-sparing criteria, 1 patient with International Federation of Gynecology and Obstetrics stage IB1 cancer, 5 patients with stage IB2, and 1 patient with stage IIA. One patient with stage IB1 cancer and 2 patients with stage IB2 cancer underwent simple vaginal trachelectomy, resection of paracervical tissues, and abdominal lymphadenectomy. Their disease-free intervals were 86, 120, and 65 months, respectively. All 3 patients had regular menses after surgery but no pregnancies, for personal reasons unrelated to fertility.ConclusionsPowerful neoadjuvant chemotherapy regimens resulted in a pathological complete response. Long-term disease-free interval was achieved after fertility-sparing management for bulky cervical cancer in 3 cases.

Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction

2017 ◽  
Vol 22 (5-6) ◽  
pp. 389-401 ◽  
Author(s):  
Yu Yang ◽  
Catherine R. Miller ◽  
Antonio Lopez-Beltran ◽  
Rodolfo Montironi ◽  
Monica Cheng ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Response ◽  
Response Prediction ◽  
Next Generation ◽  
Liquid Biopsies ◽  
Treatment Response Prediction
Sign in / Sign up

Export Citation Format

Share Document